Cargando…
A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
INTRODUCTION: Components of the hedgehog signaling pathway are upregulated in patients with idiopathic pulmonary fibrosis (IPF). Vismodegib, a small-molecule inhibitor of hedgehog signaling, when used in combination with currently available antifibrotic therapy, may be more efficacious than antifibr...
Autores principales: | Prasse, Antje, Ramaswamy, Murali, Mohan, Shaun, Pan, Lin, Kenwright, Andrew, Neighbors, Margaret, Belloni, Paula, LaCamera, Peter P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967289/ https://www.ncbi.nlm.nih.gov/pubmed/32026407 http://dx.doi.org/10.1007/s41030-019-0096-8 |
Ejemplares similares
-
Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Wencel, Mark L., et al.
Publicado: (2018) -
Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011) -
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022) -
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013) -
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)